Aprea Therapeutics picks up Series C funding

Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has secured 50 million euros in Series C financing. Redmile Group led the round with participation from Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.

ManagersNorth AmericaUSHealthcareBriefs